| Name | ATR inhibitor 2 |
|---|---|
| Synonyms |
VRT-1228692
2-Amino-6-fluoro-N-[5-fluoro-4-[4-[4-(3-oxetanyl)piperazine-1-carbonyl]-1-piperidyl]-3-pyridyl]pyrazolo[1,5-a]pyrimidine-3-cboxamide Pyrazolo[1,5-a]pyrimidine-3-cboxamide, 2-amino-6-fluoro-N-[5-fluoro-4-[4-[[4-(3-oxetanyl)-1-piperazinyl]carbonyl]-1-piperidinyl]-3-pyridinyl] MFCD31803930 M-4344 MSC-2580591A Gtisertib VX-803(M4344 ) 2-amino-6-fluoro-N-(5-fluoro-4-(4-(4-(oxetan-3-yl)piperazine-1-carbonyl)piperidin-1-yl)pyridin-3-yl)pyrazolo[1,5-a]pyrimidine-3-cboxamide VX-803 2-amino-6-fluoro-N-(5-fluoro-4-(4-(4-(oxetan-3-yl)piperazine-1-carbonyl)piperidin-1-yl)pyridin-3-yl)pyrazolo[1,5-a]pyrimidine-3-cboxamide(WXC04788) |
| Description | ATR inhibitor 2 is an ATP-competitive, orally active, and selective ATR inhibitor, with a Ki of <150 pM. ATR inhibitor 2 potently inhibits ATR-driven phosphorylated checkpoint kinase-1 (Chk1) phosphorylation with an IC50 of 8 nM. Antitumor activity[1][2]. |
|---|---|
| Related Catalog | |
| Target |
ATR:<150 pM (Ki) |
| In Vivo | In monotherapy efficacy studies ATR inhibitor 2 (VX-970, M6620) shows tumor stasis to regression in tumor models with alternative lengthening of telomeres (ALT). In combination with PARP inhibitors, tumor regression could be observed in triple-negative breast cancer xenograft models[1]. |
| References |
| Molecular Formula | C25H29F2N9O3 |
|---|---|
| Molecular Weight | 541.55 |
| Storage condition | -20°C |